What Цефокситин Treats: Main Uses and Benefits

Цефокситин is commonly used to help manage severe bacterial infections and is relevant for supportive management in surgical contexts.

Easing Symptom Burden in Serious Systemic Infections

This medication is generally used to help manage and address conditions presenting with systemic or localized discomfort, particularly moderate-to-severe bacterial infections found in deep-seated areas like the abdomen (e.g., peritonitis, abscesses) and the pelvis (e.g., pelvic inflammatory disease). It is applied in clinical settings that involve acute or unstable symptom patterns, such as pronounced fever, chills, and intense localized pain. The therapeutic focus includes infections of the abdomen, the pelvis, the lower respiratory tract (like bacterial pneumonia), and systemic conditions such as septicemia. The therapy provides support that helps ease the overall symptom burden and is applied in addressing conditions marked by increased physiological stress.

“Applied in scenarios where additional management of discomfort is required, Цефокситин supports the patient during episodes of heightened discomfort.”

Supportive Management in Surgical Scenarios

Цефокситин is relevant when supportive symptom management is appropriate in specific surgical scenarios. It is used as surgical prophylaxis and is relevant for managing the potential for postoperative infections in patients undergoing high-risk procedures, including certain gastrointestinal and gynecological surgeries. This application is often used during phases when symptoms become more noticeable (i.e., when they occur later as a complication), providing a crucial, preemptive benefit that supports the patient during episodes of heightened discomfort by easing the overall symptom load.

---

Quick Fact: Relief for Systemic Distress

This medication contributes to improved comfort during periods of heightened symptoms by helping to resolve the high fever and malaise that characterize severe, acute bacterial infection.

Regulatory References

1. DailyMed Label: Cefoxitin Injection, Powder, for Solution

Eligibility for Цефокситин (Cefoxitin) — Official Regulatory Information

Цефокситин (Cefoxitin) is a medicine with specific regulatory constraints defining who may and may not use it. These constraints are based strictly on official government labeling.

Contraindicated Populations (Must Not Use)

• Hypersensitivity: The medicine is contraindicated (use is forbidden) in patients with a known allergy or hypersensitivity to Цефокситин itself, to cephalosporin antibiotics, or to other beta-lactam antibacterial drugs (e.g., penicillins), due to the risk of severe allergic reactions.
• Formulation Sensitivity: For formulations containing dextrose, use is contraindicated in individuals with a known hypersensitivity to corn products.

Restricted and Special Consideration Populations

Population Group	Eligibility Status	Regulatory Requirement
Infants (Birth to 3 Months)	Use Not Established	Safety and effectiveness have not been established; use is not recommended in this age group.
Renal Impairment	Restricted Use	Patients with diminished kidney function require a reduction in the total daily dose to prevent high and prolonged drug concentrations.
Pregnancy/Lactation	Special Consideration	Use during pregnancy is permitted only when clearly needed. The drug is found in breast milk, requiring caution when used by nursing mothers.

General Eligibility Rule

The medicine should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria to avoid promoting drug resistance.

Interactions with Other Medicines and Products

Cefoxitin (Цефокситин) can interact with various medications, potentially altering its effectiveness or increasing the risk of adverse effects. It's crucial to inform your healthcare provider about all prescription, over-the-counter, and herbal supplements you are currently taking before starting Cefoxitin therapy.

Key Drug Interactions

Interacting Medicine	Potential Effect
Probenecid	Decreases the renal clearance of Cefoxitin, leading to higher and prolonged drug levels in the blood. This may increase the risk of side effects.
Aminoglycosides (e.g., Gentamicin, Amikacin)	Concurrent use may increase the risk of nephrotoxicity (kidney damage). Kidney function should be closely monitored.
Oral Anticoagulants (e.g., Warfarin)	May potentiate the anticoagulant effect, leading to an increased risk of bleeding. Close monitoring of coagulation parameters (like INR) is recommended.
Highly active diuretics (e.g., Furosemide)	Similar to aminoglycosides, co-administration may increase the risk of nephrotoxicity, especially in patients with pre-existing renal impairment.

Cefoxitin may also cause a false-positive reaction in tests for urinary glucose using copper-reduction methods (e.g., Clinitest) but not with enzyme-based tests (e.g., Tes-Tape). It can also interfere with the measurement of serum creatinine using the Jaffe method. Patients should inform laboratory personnel that they are receiving Cefoxitin.

️ Molecular Action: Inhibiting Bacterial Cell Wall Construction

Цефокситин (Cefoxitin) functions as a covalent inhibitor of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes vital for the final assembly of the protective cell wall. This mechanism specifically blocks the necessary transpeptidation (cross-linking) of the peptidoglycan structure, immediately compromising the microbe's integrity. The resulting cascade leads directly to bacterial cell lysis (rupture) due to internal osmotic pressure, achieving a bactericidal effect and leading to a reduction in the viable bacterial population.

---

️ Mechanistic Stability Against Bacterial Defense Enzymes

Cefoxitin's action includes a high stability against beta-lactamase enzymes conferred by its unique 7alpha-methoxy group. This structural feature prevents the enzymatic hydrolysis of the drug by many bacterial beta-lactamases. By resisting inactivation, the drug sustains its ability to bind to the PBP targets, which is essential for the mechanism to proceed in the presence of beta-lactamase enzymes.

Official Instructions for Use: Cefoxitin

Cefoxitin is an antibiotic administered parenterally (by injection or infusion), strictly according to professional medical instructions. It is supplied as a powder for injection that requires reconstitution and dilution prior to use.

Approved Administration Routes and Form

Administration Route	Official Dosage Form
Intravenous (IV) Injection	Powder for Injection (reconstituted)
Intravenous (IV) Infusion	Powder for Injection (reconstituted and diluted)
Intramuscular (IM) Injection	Powder for Injection (reconstituted)

Dosage and Frequency

Standard dosage, typically 1 g to 2 g, is administered at fixed intervals, most often every 6 or 8 hours (Q6H or Q8H), depending on the severity of the condition. For severe infections, the dose may be increased, up to a maximum daily limit of 12 g.

Preparation and Special Conditions

1. Reconstitution: The powder must be mixed with a specific diluent (such as Sterile Water for Injection). For IM use, lidocaine solution may be utilized for reconstitution.
2. IV Administration: The final solution for IV injection must be administered slowly, typically over 3 to 5 minutes. For infusion, the reconstituted drug must be further diluted in an approved solution (e.g., 0.9% Sodium Chloride).

Population-Specific Instructions

• Kidney Impairment: Dosing must be adjusted in patients with reduced kidney function. The maintenance dose and the interval between doses must be altered based on the patient's creatinine clearance.
• Pediatrics (ge 3 Months): Dosage is based on body weight, usually in the range of 80–160 mg/kg per day, divided into four to six doses.

Therapy for certain bacterial infections (e.g., Group A Beta-Hemolytic Streptococci) requires a minimum course duration, such as 10 days.

Research Evidence / Overview of Studies for Цефокситин

Evidence for Use in Surgical Prophylaxis

Clinical research for Цефокситин in surgical prophylaxis, or the prevention of postoperative infection, was studied for its use in preventing postoperative infections. These research efforts were primarily conducted through Randomized Controlled Trials (RCTs) and systematic reviews. This research was applied in studies involving patients undergoing high-risk procedures, such as colorectal surgery, hysterectomies, and cesarean sections. The researchers examined outcomes related to physical discomfort and the development of Surgical Site Infections (SSI) in the immediate period following the procedure. Trial summaries reported patterns observed in studies that explored prevention of infection when used in studies that used comparisons to other treatments or inactive substances. Results apply only to the populations studied. Certainty remains low regarding long-term effects, as follow-up durations were often limited to 30 days or less.

Evidence for Use in Treating Intra-Abdominal Infections

Studies exploring Цефокситин's use in conditions such as peritonitis and abdominal abscesses were generally designed as comparative trials. These research efforts examined temporary physiological imbalance within patients who had established, active infections, often involving a mix of aerobic and anaerobic bacteria. Researchers monitored outcomes by measuring both clinical cure rates (whether the patient recovered from the infection) and bacteriological response (whether the targeted bacteria were eradicated). Studies monitored responses over defined time intervals and reported how symptoms evolved in the observed populations. A key limitation is that many of the core trials establishing the initial patterns of response are older, and information about the drug's performance against currently circulating resistant bacteria is limited.

What is Still Uncertain About the Research

Across all studied indications, there is limited information for long-term outcomes, as most clinical trials were designed to capture short-term outcomes, typically monitoring patients only up to 30 days. The research provides context but not individual predictions. Furthermore, data are still emerging and remain insufficient for specific patient groups, such as children and those with certain complex coexisting conditions, meaning results apply primarily to the general adult populations studied.

Key Studies & References

1. Mefoxin (Cefoxitin for Injection) Highlights of Prescribing Information (US FDA Label)
2. Complicated Intra-Abdominal Infections: Developing Drugs for Treatment Guidance for Industry (HHS/FDA)

Common questions about Цефокситин (FAQ)

Q: What unusual side effects can occur from Cefoxitin?

The official safety profile categorizes adverse events by frequency. Reactions considered unusual or rare include serious events such as acute renal failure, jaundice (yellowing of the skin or eyes), and convulsions.

The regulatory profile lists all reported reactions, regardless of how often they occur.

Q: How does Cefoxitin affect gut flora?

According to the official product information, treatment with antibacterial agents, including Cefoxitin, alters the normal flora of the colon.

This change in the balance of bacteria creates a risk for a serious reported adverse reaction known as Clostridium difficile-associated diarrhea (CDAD).

Q: Why is Cefoxitin given by injection and not in tablet form?

Cefoxitin is a semi-synthetic cephamycin antibiotic formulated specifically for parenteral administration, meaning it is delivered only by intravenous (IV) or intramuscular (IM) injection.

The official drug label and product information do not list an oral form.

Q: Are there long-term side effects associated with Cefoxitin use?

Official regulatory warnings indicate that prolonged use of this or any antibiotic may result in the overgrowth of nonsusceptible organisms, which is known as a superinfection.

Superinfection is the primary long-term risk detailed in the precautions section of the official drug label.

Q: Is special care needed for the injection site?

The official adverse reactions list confirms that local reactions are commonly reported at the injection site.

These reported effects include thrombophlebitis (a clot or inflammation in the vein) with intravenous administration, and induration, pain, and tenderness with intramuscular administration.

Q: Are there special safety considerations for the elderly when using Cefoxitin?

Regulatory documents indicate that elderly patients are more likely to have age-related kidney problems.

Due to this potential for reduced kidney function, official instructions require that the dose be adjusted based on the patient's renal status to manage drug concentrations.

Q: What is a 'penicillinase inhibitor' and how does it relate to Cefoxitin?

Cefoxitin is not classified as a dedicated penicillinase inhibitor, but its unique structure provides high stability against these destructive bacterial enzymes, known as beta-lactamases (which include penicillinases).

This structural feature helps the drug remain effective against certain bacteria that produce these enzymes.

Q: Why is Cefoxitin classified as a second-generation cephalosporin?

Cefoxitin is chemically a cephamycin, but it is often categorized alongside the second-generation cephalosporins.

This classification is based on its specific chemical structure and its defined spectrum of activity, which includes effectiveness against various Gram-positive, Gram-negative, and notably, anaerobic bacteria.

Q: How quickly does Cefoxitin start working?

The drug's official pharmacokinetic data indicate how quickly it reaches its maximum concentration in the blood.

The mean peak concentration in the serum is reached at 20 to 30 minutes after intramuscular injection and within 5 minutes after intravenous injection.

Q: How long does Cefoxitin stay in the body?

According to the official clinical pharmacology data, the drug has a short half-life of approximately 41 to 59 minutes in patients with normal kidney function.

About 85% of the dose is excreted unchanged by the kidneys over a 6-hour period.

Q: Does Cefoxitin affect the ability to drive?

Regulatory documents warn of a potential major influence on the ability to drive or use machinery.

This caution is issued due to the possible risk of Central Nervous System (CNS) effects, such as encephalopathy (confusion or seizures).

Q: Does Cefoxitin interact with alcohol?

Regulatory-linked summaries indicate a moderate interaction with alcohol.

This combination may increase the risk of side effects such as dizziness, drowsiness, and stomach upset.

Q: Are there any dietary changes needed while using Cefoxitin?

Based on regulatory-linked summaries, there is no sufficient scientific evidence regarding the safety or necessity of concurrent use with any particular food.

Therefore, the drug label does not specify general dietary restrictions.

Q: Can Cefoxitin cause headache or dizziness?

Yes, headache and dizziness are reported adverse effects listed in the official safety profile.

These effects are typically reported as infrequent or rare occurrences.

Q: How does Cefoxitin affect body temperature?

Fever (elevated temperature) is included in the list of adverse reactions in the official safety profile.

Fever may be associated with allergic reactions or, in rare cases, with severe conditions like Clostridium difficile colitis.

Q: Can Cefoxitin cause sleep problems?

Rare adverse reactions listed in the official safety profile include Central Nervous System (CNS) effects that could potentially interfere with normal function.

These reported CNS effects include agitation, confusion, hostility, irritability, and lethargy.

Q: What types of bacteria does Cefoxitin fight most effectively?

The drug is active against most strains of certain Gram-positive bacteria, Gram-negative organisms, and is particularly noted in regulatory documents for its activity against anaerobic bacteria.

Detailed susceptibility information is available in the official microbiology section.

Q: Can Cefoxitin cause darkening of urine?

Yes, dark-colored urine is a reported adverse event in the drug's safety profile.

This symptom is often associated with other, more serious, rare liver-related issues like jaundice.

Q: Can it cause mood changes?

Yes, rare adverse reactions listed in the official safety profile include Central Nervous System (CNS) effects that relate to mood or behavior.

These reported changes include depression, agitation, confusion, hostility, and irritability.

Official Storage and Disposal Profile for Cefoxitin

This information is based on authoritative government regulatory documents for Cefoxitin sodium, supplied as a powder for injection/infusion.

Requirement	Official Statement Summary
Unopened Powder Storage	Store below 25 C or 30 C (room temperature), varying by label. Do not use after the expiration date.
In-Use Stability (Reconstituted)	Chemical stability is limited, typically 4 to 8 hours at 25 C. The product must be used immediately from a microbiological safety perspective.
Child Safety	Keep this medicine out of the sight and reach of children.
Disposal Instructions	Any unused product and waste material must be disposed of in accordance with local requirements. Do not dispose of the medicine via wastewater or household trash unless specifically instructed.

Official labeling mandates temperature control for the dry powder and strict time limits for the prepared solution, after which it must be discarded. Disposal rules prohibit flushing the product to help protect the environment.